Krystal Biotech to Report Second Quarter 2026 Financial Results on August 3, 2026
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Krystal Biotech (NASDAQ: KRYS) will report its second quarter 2026 financial results on Monday, August 3, 2026, before the U.S. market opens. Management will host a conference call and webcast at 8:30 a.m. ET that day. A live webcast will be available online, with a replay accessible for at least 30 days via the Investors section of the company’s website.
Details
News Market Reaction – KRYS
On Jul 24, the first trading day after this news, KRYS closed 2.35% above the previous close.
Data tracked by StockTitan Argus for the Jul 24 session.
Key Figures
- Reporting period
- Q2 2026
- Financial results scheduled for August 3, 2026
- Reporting date
- August 3, 2026
- Results scheduled prior to the open of U.S. markets
- Conference call time
- 8:30 am ET
- August 3, 2026 financial-results webcast and business update
- Replay availability
- At least 30 days
- Replay available on the Investors section of the company website
Previous Earnings date Reports
-
Scheduled first-quarter results and an 8:30 AM ET management webcast
-
Scheduled fourth-quarter and full-year results before market open
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PITTSBURGH, July 23, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that it will report its second quarter 2026 financial results on Monday, August 3, 2026, prior to the open of U.S. markets.
The Company’s management will also host a conference call and webcast at 8:30 am ET on Monday, August 3, 2026, to discuss the financial results and provide a business update.
Investors and the general public can access the live webcast at: https://www.webcaster5.com/Webcast/Page/3018/54300.
For those unable to listen to the live webcast, a replay will be available for at least 30 days on the Investors section of the Company’s website at www.krystalbio.com.
About Krystal Biotech, Inc.
Krystal Biotech, Inc. (NASDAQ: KRYS) is a fully integrated, commercial-stage, global biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK®, the Company’s first commercial product, is the first-ever redosable gene therapy and the first genetic medicine approved in the United States, Europe, and Japan for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. Visit www.krystalbio.com to learn more or follow us on LinkedIn and X.
CONTACT
Investors and Media:
Stéphane Paquette, PhD
Krystal Biotech
spaquette@krystalbio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.